Aβ immunotherapies with anti-Aβ antibody responses have high potential as possible prevention treatment for Alzheimer's disease. We have previously shown that active DNA Aβ1-42 immunization via gene gun delivery led to a non-inflammatory immune response resulting in decreased Aβ levels in brains of an immunized AD mouse model. To make DNA vaccination more applicable for clinical use, we used here intradermal electroporation. With fine tuning of the electropulse parameters, high antibody levels and low levels of inflammatory cytokines in the cellular immunoassays were observed. Full-length DNA Aβ1-42 immunization delivered via electroporation has potential to be used in the clinical setting.
Introduction
A major challenge of our society is finding a prevention treatment or cure for Alzheimer's disease (AD). Treatment options are only symptomatic and shown some improvement in the early stage of the disease, but there is currently no effective treatment addressing underlying causes nor is there a cure for AD. As AD is the leading form of agerelated dementia and with an increase of life expectancy worldwide, the social and economic burden from this disease will increase dramatically. It is projected that the number of people age 65 and older who have Alzheimer's disease in the United States may triple, from 5.1 million in 2015 to 13.8 million by 2050 (Alzheimer's Association Report, 2015) . AD is a slow and in regard to clinical findings very variable disease. AD pathogenesis has been associated with the accumulation, aggregation and deposition of amyloid beta (Abeta, Aβ) peptides and hyperphoshorylation of tau in the brain. The amyloid cascade hypothesis postulates that Aβ deposition is an initial event in a multifactoral pathogenesis, and studies have shown that Aβ deposition precedes AD symptoms by at least 20 years (Hardy, 1996; Selkoe, 1996; Hardy and Selkoe, 2001; Bateman et al., 2012) . Therapy approaches using active and passive immunizations against Aβ have a high possibility to be effective in removing amyloid from brain, and might thus prevent or lessen downstream pathology. Since 2000 a number of clinical trials for AD immunotherapy have started, have failed, and are continued (Orgogozo et al., 2003; Fox et al., 2005; Gilman et al., 2005; Salloway et al., 2009; Adolfsson et al., 2012; Bohrmann et al., 2012; Farlow et al., 2012; Relkin et al., 2008; Blennow et al., 2011; Abbott and Dolgin, 2016) . In one of the most recent clinical trials using passive immunization with an antibody that targets aggregated Aβ, soluble oligomers and insoluble fibrils Aβ42, the results in patients with prodromal or mild AD showed that brain Aβ had been reduced in a doseand time-dependent manner. In addtion after a year of monthly intravenous infusions of this antibody, functional benefits such as slowing of clinical decline were measured leading to continuation of this treatment into a Phase 3 clinical trial (Sevigny et al., 2016) .
Arguments for the lack of more definitive positive results from the completed clinical trials in AD (active and passive immunizations) are that treatment was started too late (Miller, 2012) . Studies started in 2013 have the focus on therapy in patient cohorts before the onset of clinical symptoms of AD (Miller, 2012; Morris et al., 2012; Reiman et al., 2011) . When these prevention studies using mainly passive immunizations with anti-Aβ antibodies and β secretase inhibitors provide functional benefits for AD patients and delays in onset of the disease, the development of active immunotherapy will be in demand as active vaccinations can be applied easier and more economically to large populations.
Immunization against a self-antigen is challenging as it might cause autoimmune inflammation as in did in AN1792 (Orgogozo et al., 2003; Fox et al., 2005; Gilman et al., 2005) . Using DNA Aβ1-42 immunization into the skin with a ballistic device, the Helios gene gun, we showed a predominantly Th2-type antibody response indicative of a non-inflammatory immune response and the disappearance of an Aβ42
